Novartis CEO Vas Narasimhan backs the company’s current M&A strategy, which is mainly focused on bolt-on deals under $2bn.
• Source: Archive
Novartis booked a $1.9bn partial impairment on del-desiran after the drug’s Phase III failure, but CEO Vas Narasimhan said the hit to its $12bn Avidity Biosciences acquisition does not change a strategy built on bolt-on deals under $2bn.
Key TakeawaysNovartis took a $1.9bn partial impairment on del-desiran after its Phase III failure, and a further pivotal study in myotonic dystrophy type 1 will delay any launch.
Speaking to reporters after third-quarter results, Narasimhan said the combined effect of the del-desiran and…